Isorhapontigenin protects against doxorubicin-induced cardiotoxicity via increasing YAP1 expression

• Główni autorzy: Panxia Wang (Autor), Minghui Wang (Autor), Yuehuai Hu (Autor), Jianxing Chen (Autor), Yanjun Cao (Autor), Cui Liu (Autor), Zhongkai Wu (Autor), Juan Shen (Autor), Jing Lu (Autor), Peiqing Liu (Autor)
• Format: Książka
• Wydane: Elsevier, 2021-03-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

As an effective anticancer drug, the clinical limitation of doxorubicin (Dox) is the time- and dose-dependent cardiotoxicity. Yes-associated protein 1 (YAP1) interacts with transcription factor TEA domain 1 (TEAD1) and plays an important role in cell proliferation and survival. However, the role of...